Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
Andrew Leonard Laccetti(New York University), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Landon C. Brown(Atrium Health Wake Forest Baptist), Eric Jonasch(The University of Texas MD Anderson Cancer Center), Amishi Y. Shah(The University of Texas MD Anderson Cancer Center), Daniel J. George(Duke University), Chester Kao(Sidney Kimmel Comprehensive Cancer Center), Andrew J. Armstrong(Duke University), Aradhana M. Venkatesan(National Institutes of Health), Benjamin Garmezy(Sarah Cannon), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Paul G. Corn(Cornell University), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Jianjun Gao(Chinese General Hospital College of Nursing and Liberal Arts), Pavlos Msaouel(The University of Texas MD Anderson Cancer Center), Rajan T. Gupta(Duke University), Emily N. Kinsey(Duke Medical Center), Minas P. Economides(NYU Langone Health), Michael R. Harrison(Pfizer (United States)), Tian Zhang(Duke Medical Center), Amado Zurita‐Saavedra(The University of Texas MD Anderson Cancer Center)
Cited by 19
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
|Molecular Cancer Research|2011|650